Your browser doesn't support javascript.
loading
CRI iAtlas: an interactive portal for immuno-oncology research.
Eddy, James A; Thorsson, Vésteinn; Lamb, Andrew E; Gibbs, David L; Heimann, Carolina; Yu, Jia Xin; Chung, Verena; Chae, Yooree; Dang, Kristen; Vincent, Benjamin G; Shmulevich, Ilya; Guinney, Justin.
Afiliação
  • Eddy JA; Sage Bionetworks, Seattle, WA, 98101, USA.
  • Thorsson V; Institute for Systems Biology, Seattle, WA, 98109, USA.
  • Lamb AE; Sage Bionetworks, Seattle, WA, 98101, USA.
  • Gibbs DL; Institute for Systems Biology, Seattle, WA, 98109, USA.
  • Heimann C; Institute for Systems Biology, Seattle, WA, 98109, USA.
  • Yu JX; Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, 10006, USA.
  • Chung V; Sage Bionetworks, Seattle, WA, 98101, USA.
  • Chae Y; Sage Bionetworks, Seattle, WA, 98101, USA.
  • Dang K; Sage Bionetworks, Seattle, WA, 98101, USA.
  • Vincent BG; University of North Carolina, Chapel Hill, NC, 27599, USA.
  • Shmulevich I; Institute for Systems Biology, Seattle, WA, 98109, USA.
  • Guinney J; Sage Bionetworks, Seattle, WA, 98101, USA.
F1000Res ; 9: 1028, 2020.
Article em En | MEDLINE | ID: mdl-33214875
ABSTRACT
The Cancer Research Institute (CRI) iAtlas is an interactive web platform for data exploration and discovery in the context of tumors and their interactions with the immune microenvironment. iAtlas allows researchers to study immune response characterizations and patterns for individual tumor types, tumor subtypes, and immune subtypes. iAtlas supports computation and visualization of correlations and statistics among features related to the tumor microenvironment, cell composition, immune expression signatures, tumor mutation burden, cancer driver mutations, adaptive cell clonality, patient survival, expression of key immunomodulators, and tumor infiltrating lymphocyte (TIL) spatial maps. iAtlas was launched to accompany the release of the TCGA PanCancer Atlas and has since been expanded to include new capabilities such as (1) user-defined loading of sample cohorts, (2) a tool for classifying expression data into immune subtypes, and (3) integration of TIL mapping from digital pathology images. We expect that the CRI iAtlas will accelerate discovery and improve patient outcomes by providing researchers access to standardized immunogenomics data to better understand the tumor immune microenvironment and its impact on patient responses to immunotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Limite: Humans Idioma: En Revista: F1000Res Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Limite: Humans Idioma: En Revista: F1000Res Ano de publicação: 2020 Tipo de documento: Article